ALMATICA
Big PharmaALMATICA is a major pharmaceutical company focused on Infectious Disease, Cardiovascular. Key products include LOREEV XR.
ALMATICA's Key Drugs
ALMATICA's core commercial portfolio centers on LOREEV XR, GRALISE, ESCITALOPRAM, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
ALMATICA's Recent FDA Approvals
ALMATICA secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
ALMATICA's Therapeutic Areas
ALMATICA's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALMATICA's Top Competitors
ALMATICA's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALMATICA Pipeline Snapshot
Active clinical trials for ALMATICA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LOREEV XR leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling